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In patients with lupus nephritis, progression from a mild lesion to a diffuse proliferative
glomerulonephritis has been reported in one to 35 percent of patients. Because of the wide
variation in the rate of progression, this study was undertaken to determine those factors which
would identify the patients most likely to progress. Of21 patients with a mild lupus nephritis by
light microscopy, progression to a diffuse proliferative lesion was seen in only those patients
who had subendothelial deposits. While not all patients with subendothelial deposits had a
deteriorating course, the persistence of such deposits on subsequent biopsies indicated a poor
prognosis.
INTRODUCTION
Over the past several years, increasing attention has been directed toward mild
proliferative lesions in the kidneys of patients with systemic lupus erythematosus
[5,8,9,11,15,18,19]. While some investigators have reported that mild proliferative
lesions are associated with a good prognosis [5,18], others have described a more
ominous course with progression of the histopathologic lesion and clinical deteriora-
tion [10,19]. Several factors might account for this variability in the clinical outcome
of patients with mild lupus nephritis: differences in the definition of the lesions
described, different therapeutic approaches, small numbers ofpatients in some series,
and a lack of consistent and reproducible histopathologic classification. Conse-
quently, the clinicopathologic correlates of a mild proliferative lupus nephritis have
been uncertain and require additional clarification.
In the present report, a broad definition of a mild proliferative lesion has been
adopted in order to include the full spectrum of similar lesions described by others
[5,8,11,18,19]. By light microscopy, the lesions included might have been termed
focal proliferative, minimal changes, or pure mesangial proliferative. The purpose of
this report is to emphasize the importance ofthe location of electron dense deposits
on ultrastructural examination of these lesions. Despite similar changes on light
microscopy, a progressive clinical course was seen only in patients with subendothel-
ial deposits.
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Over an eight-year period, 72 patients with SLE have had a renal biopsy performed
after informed consent had been obtained. Renal biopsy specimens were processed
for light and electron microscopy as previously described [12]. A minimum of six
glomeruli were present on light microscopic sections, and all the capillary loops of a
composite cross section of each of at least three glomeruli were examined by electron
microscopy. Careful evaluation of thin-sectioned material stained with Jones silver
methenamine confirmed a generalized pattern of deposits in all the glomeruli
available for light microscopy in each biopsy. Based on both light and electron
microscopy, our classification of lupus nephropathy has been previously described in
detail [14].
On light microscopy, a mild proliferative lesion is defined by a slight but definite
increase in the cellularity of the glomerular capillary tuft or mesangial region. The
pattern of proliferation may vary from segmental changes to mild global changes
which involve less than 50 percent of the glomeruli present [14].
Twenty-three patients had a mild proliferative lesion on light microscopy. Ade-
quate material for evaluation of light and electron microscopic changes was available
in 21 of the 23 patients. These 21 patients, who were selected on the basis of renal
changes on light microscopy, form the basis of this report.
All patients had clinical and serological evidence to confirm the diagnosis of
systemic lupus erythematosus [6], and none of these patients had been treated for
more than four months prior to the first renal biopsy. The clinical course was
reviewed and parameters of renal function, including BUN, serum creatinine, and 24-
hour protein excretion, were assessed. Serum creatinine was measured by Jaffe
reaction on dialyzed serum, which measures dialyzable total chromagen, and normal
values in our laboratory are 0.6-1.5 mg/dl. The third component ofcomplement(C3)
was measured by the radial immunodiffusion method. Serum antibody to ds-DNA
was assayed by a modification of the Farr technique [16] as previously described in
detail [4].
The renal biopsy findings of these patients with mild proliferative glomeruloneph-
ritis on light microscopy were further classified on the basis of the ultrastructural
examination (Fig. 1). The 21 patients were divided into three groups. The first group,
Group A, consisting of six patients, was characterized by the absence of electron
dense deposits. The second group, Group B, was composed of five patients who had
electron dense deposits limited to the mesangial area. The third group, Group C, of
ten patients had subendothelial deposits along the peripheral capillary loop, usually
accompanied by mesangial and sometimes subepithelial deposits. Some of the
patients in this third group have been reported in a previous study of SLE nephritis
associated with subendothelial deposits [13].
The patients in Groups A and B received anti-inflammatory agents and steroids for
the control of the extra-renal manifestations of their SLE. A specific protocol was
not used for therapy of the patients in Groups A and B and the dosage of prednisone
averaged 10-15 mg/day. Patients in Group C were treated with a specific drug
regimen which included prednisone and azathioprine [12,13]. For the Group C
patients, prednisone was initially started at 40-60 mg/day and tapered over the first
six months to a dose of 10-15 mg/day, if the clinical manifestations of SLE had
improved. Azathioprine was given in a dose of 2-3 mg/kg/ day; no attempt was made
to induce leukopenia and the drug was withheld if the white blood cell count fell
below 3,000 per mm3 and then restarted at a dose of 0.5 mg/kg less than the initial
dose when WBC returned to normal. One of the patients in Group B and three
patients from Group C were treated with cyclophosphamide (1-2 mg/kg/day).
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FIG. 1. Ultrastructural classification of the patients with a mild proliferative lupus nephritis. Panel
A (top), no electron dense deposits are present; Panel B (center), deposits are limited to the mesangial
region; Panel C (bottom), subendothelial deposits are located along the peripheral capillary loop.RESULTS
Clinical characteristics of the patients in each group are shown in Table 1. The
mean age at the onset of clinical symptoms of SLE was comparable for all groups
(Group A, 25 years; Group B, 19.6 years; and Group C, 18.9 years). Sex ratios were
similar for each group with a female predominance as expected. The duration of
renal abnormalities, usually proteinuria or abnormal urinary sediment, prior to
biopsy ranged from zero to seven months. Two patients from Group A, four from
Group B, and three from Group C had no clinical evidence of renal involvement at
the time of initial biopsy.
Initial laboratory studies were very similar for all groups. Renal function, as
reflected by serum creatinine values, was within the normal range for our labora-
tory. Only one patient (NM) had a serum creatinine greater than 1.5 mg/dl. All of
the patients in Groups A and B had 24-hour urinary protein excretion less than
1.0 gm/day. In contrast, five of ten patients in Group C had significant protein-
uria (1.6-6.0 gm/day).
DNA binding capacity (DNA-bc) was available from the time of initial biopsy in
15 patients. Significantly elevated values (greater than 20 percent) occurred in 13 of
the patients. The range of values was similar in each group. C3 values were low in all
patients in Group C, while three patients in Group A and two in Group B had normal
C3 levels at the time of initial biopsy (normal range 78-140 mg/dl).
The mean period of follow-up was 45 months with a range from 12 to 96 months.
TABLE I
Summary of Initial Clinical and Laboratory Data
Duration of
Age at Renal Symptoms Serum Protein
Biopsy Prior to Bx Creatinine Excretion DNA-bc C3
Patient (yrs) Sex (months) mg/dl Gm/day % mg/dl
Group A: (No electron dense deposits)
RD 31 M 0 1.0 <0.2 - 51
KB 14 F 1 0.9 <0.2 86 89
YK 13 F 1 0.6 <0.2 - 105
LC 15 F 0 0.8 <0.2 47 56
AR 19 F 1 1.0 0.35 91 53
OC 60 F 6 1.6 <0.2 10 86
Group B: (Mesangial electron dense deposits only)
NM 29 F 3 1.1 0.8 18 64
NE 13 F 0 0.7 <0.2 - 84
AD 28 F 0 1.0 0.5 53 59
WC 11 M 0 0.8 <0.2 74 116
JC 17 F 0 0.9 <0.2 60 30
Group C: (Subendothelial electron dense deposits)
FA 42 F 0 1.0 <0.2 48 42
JN 15 F 6 1.4 2.7 94 60
NC 15 F 0 1.1 <0.2 56 52
JK 11 M 1 1.2 3.4 35 44
BR 22 F 0 1.0 <0.2 - 54
AB 16 M 3 1.0 0.6 97 75
NM 32 F 4 1.6 5.0 - 58
DG 7 F 1 0.7 1.6 - 56
LR 15 F 2 1.2 0.5 94 40
MA 14 F 7 1.0 6.0 98 36
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The mean duration of follow-up was not significantly different among each of the
groups (Group A, 50 months; Group B, 40 months; and Group C, 47 months).
The clinical course of the patients in Group A was not associated with the
development of increased proteinuria or diminished renal function. One patient (AR)
in this group died ofsevere CNS lupus. At the time ofher terminal episode, her serum
creatinine was 1.0 mg/dl and her urinary protein excretion was <0.1 gm/dl. The
other five patients in this group have done quite well. None of the patients in this
group has had a repeat renal biopsy.
In Group B, four of the five patients have had an uncomplicated clinical course.
These four patients have had stable renal function with serum creatinine less than
1.5 mg/dl and stable or decreasing proteinuria. One(NM) ofthesefour patients with
a stable course had a second renal biopsy which demonstrated adisappearance ofall
electron dense deposits (Fig. 2). One patient (JC) in Group B had a more complicated
clinical course. Within five months of the initial biopsy, this patient developed
increased proteinuria to greater than 5.0 gm/d, and a repeat renal biopsy revealed a
membranous lesion, with mesangial and subepithelial deposits on electron micros-
copy. Approximately 18 months later, this patient experienced a majorexacerbation
of her SLE when all of her medications were discontinued. After two months of
diminished renal function, her serum creatinine returned to 1.3 mg/dl while on
cyclophosphamide and prednisone. A third renal biopsy continued to demonstrate
only membranous changes with subepithelial and mesangial deposits on electron
microsopy. No subendothelial deposits were found in any of her biopsy specimens.
Overall, the patients in Group B have done reasonably well. None ofthe patients has
developed permanent renal insufficiency and none has developed clinical evidence of
a severe diffuse proliferative lupus nephritis.
In contrast, the clinical course of patients with subendothelial deposits (Group C)
has been more ominous. Despite intensive therapywith prednisone and azathioprine,
five patients in this group have had a progressive and deteriorating clinical course
marked by increased proteinuria (greater than 3.0 gm/d) and/or reduced renal
function (serum creatinine < 1.5 mg/dl). Two of these five patients died in renal
failure, one is on chronic hemodialysis, and two have stabilized after substituting
cyclophosphamide for azathioprine in their treatment regimen. All five of these
patients have had a second renal biopsy (Fig. 2). In each case, there has been a
progression to a severe diffuse and global proliferative lesion on light microscopy and
persistence ofsubendothelial deposits on electron microscopy. The other five patients
inf this group have had stable or improving renal function. One (FA) of these five
Ist Biopsy Mesangial Deposits Subendothelial Deposits
(Group B) (Group C)
/ \1 22 2 5
Repeat Subepithelial No No Subepithelial Subendothelial
Biopsy Deposits Deposits Deposits Deposits Deposits I t I
Clinical Increased Stable or Improving Renal
Course Proteinuria Insufficiency
FIG. 2. Clinicopathologic correlates in mild lupus nephritis.
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gm/d proteinuria at her demise. Repeat renal biopsies have been done in four ofthese
patients with a stable/improved clinical course (Fig. 2). In each case, light micros-
copy continued to reveal a mild proliferative lesion. On ultrastructural examination,
two patients had no deposits and two patients had only subepithelial and mesangial
deposits. Subendothelial deposits were not seen on subsequent renal biopsies in any
of the four patients who improved.
In Group C, one-half the patients had stable or improving renal function and the
other half experienced a progressive decline in their renal status. Renal deterioration
was associated with persistence of subendothelial deposits on electron microscopy
and progression to a diffuse and global proliferative lesion on light microscopy.
Stable or improving renal function was associated with disappearance of subendo-
thelial deposits and continued mild proliferative changes.
The initial DNA-bc was not a reliable index ofthe subsequent clinical course. This
may be related to certain problems with the methodology of the Farr assay which
have been recently reviewed by Aarden and co-workers [1,2,3]. These investigators
emphasized that since the assay is predominantly for the detection of antibodies to
double-stranded DNA that binding may be altered by factors such as molecular size,
the presence of single-stranded regions, or contamination with other proteins. In
recognition of these problems, we have employed a carefully standardized technique
for determination of DNA-bc. Moreover, since the same technique was used
throughout in the present study, the serial pattern of DNA-bc could be correlated
with the serial histologic findings and patients' clinical course. As reported previously
[4,13], DNA-bc tended to remain elevated longer in patients who subsequently had
renal deterioration. Serial DNA-bc were available in 18 patients (nine in Group C
and nine in Groups A and B). Five patients in Group C and nine patients in Groups A
and B experienced a decrease in DNA-bc to values less than 40 percent by six months
after initiation of treatment. In each case, these 14 patients had a favorable clinical
outcome. Four patients in Group C had persistently elevated DNA-bc (greater than
70 percent) for as long as 24 months after onset, and all four patients experienced a
deterioration in renal function.
DISCUSSION
A mild proliferative glomerulonephritis has been described in patients with SLE
since the earliest classifications of lupus nephritis [7,17]. Because of the variability in
terminology between investigators, these lesions have been termed focal proliferative,
minimal change, or mild mesangial proliferative. Although generally considered to
carry a favorable prognosis, histologic progression and clinical deterioration have
been described in some patients with these mild lesions. In fact, over the past 13
years, approximately 175 patients with mild proliferative lupus nephritis have been
reported [19], and histopathologic progression has been noted in one to 35 percent of
reported series [19]. In the vast majority of these reports, the lesions have been
examined by light microscopy alone, or insufficient data regarding ultrastructural
changes are provided to allow an analysis of the importance of electron dense
deposits. Several investigators have noted, however, a direct relationship between the
severity of renal disease and the degree and extent ofsubendothelial deposits [5,9,1 1].
Only one previous report has dealt specifically with the importance ofsubendothelial
deposits in mild proliferative lesions [19].
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The present study was designed to evaluate those factors which might allow the
identification of patients with mild lupus nephritis who would be at risk for a poor
outcome. In the present study, the patients in Groups A or B and those patients in
Group C differ in three respects: (1) Group C patients all had subendothelial deposits
on their renal biopsies, (2) Group C patients were treated more intensely with steroids
and immunosuppressive drugs, and (3) histopathologic progression and permanent
reduction in renal function were seen only in Group C patients. It seems unlikely that
the relatively poor outcome for the Group C patients was related to either excessive
or inadequate therapy. Since none of the Group C patients developed complications
such as opportunistic infections which could be related to excessive drugtherapy and
since other patients with similar or even more extensive renal involvement have
shown improvement, rather than progressive deterioration on the same drug protocol
[13], it seems unlikely that the therapeutic regimen in these patients was excessive.
The rate of progression in the Group C patients (5/10) is not significantly different
(X2 = 0.5; P = NS) from that in other patients with subendothelial deposits but more
severe changes on light microscopy (6/21) who were treated with the same drug
regimen [12,13]. In the present report, renal deterioration occurred in five of 21
patients with mild lupus nephritis on light microscopy, which is quite similar to the
incidence of progression previously reported by Ginzler in nine of 31 patients [10],
and by Zimmerman in six of 17 patients [19]. Therefore, it does not appear that either
excessive or inadequate therapy has significantly biased clinical progression in the
Group C patients since the rate of progression in this group, as a whole, is
comparable with that in the current literature [10,19].
Although the patients who developed histopathologic progression and permanent
reduction in renal function tended to have clinical evidence of more active disease at
onset, the wide range of values in each group precluded the identification of those
patients on clinical data alone. The degree of histopathologic changes by light
microscopy was similar among all patients. The patients who progressed to a more
severe diffuse and global proliferative lesion and who developed a sustained fall in
renal function were characterized by: (1) subendothelial deposits on the initial renal
biopsy, (2) persistence of the subendothelial deposits on a repeat renal biopsy 18-24
months after initiation of therapy, and (3) persistently elevated DNA-bc. Patients
with a mild proliferative lesion whose renal status remained stable or improved were
identified by: (1) either no deposits or only mesangial deposits on the initial renal
biopsy, or (2) the disappearance of subendothelial deposits on subsequent renal
biopsies, and (3) a pattern of progressive improvement in DNA-bc.
This analysis of patients with mild lupus nephritis confirms Zimmerman's observa-
tion that patients at risk for progression cannot be clearlydefined byclinical features
or histopathologic changes on light microscopy alone [19]. The present study
provides two additional observations. First, while patients with subendothelial
deposits are at greatest risk for a deterioration in renal status, not all patients with
subendothelial deposits will progress, but the persistence of such deposits on
subsequent renal biopsies is associated with clinical progression. Secondly, the
pattern of change in DNA-bc is a helpful prognostic indicator in this group of pa-
tients with mild renal disease in a manner similar to that previously reported in pa-
tients with more severe renal lesions [13]. Patients with mild lupus nephritis on light
microscopy but subendothelial deposits on ultrastructural examination require
careful follow-up and may need intensive therapy to prevent progressive renal
changes.
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